Speaker Profile
MD, Chief Scientific Officer, Nucleix
Biography
Mathias Ehrich, M.D., has more than 20 years of experience successfully developing, implementing and commercializing cutting-edge scientific technologies and clinical applications. Throughout his career, Dr. Ehrich has specialized in circulating cell-free DNA, epigenetics and oncology, and has launched more than 20 products across multiple categories, including instrumentation, reagents, clinical assay and collection devices. Previously, Dr. Ehrich co-founded Juno Diagnostics, where he built the foundational technology stack of in-home genetic testing devices, which led to the creation of four novel patent families. Dr. Ehrich has authored or co-authored more than 50 peer reviewed publications, owns more than 15 patents and patent applications, and has written multiple book chapters on genomics and DNA sequencing. Dr. Ehrich began his career in the medical industry as a trained physician and received his M.D. from the University of Hamburg in Germany.
Talk
Epigenetic Detection of Early Stage Lung Cancer
Nucleix will demonstrate the strength of its technology and differentiated approach to detecting cancer earlier to benefit physicians and patients, share results from the EpiCheck Lung Cancer Atlas, provide an update on its Sightline clinical study, which is currently enrolling 5,000 highrisk current and former smokers and share initial performance data for Lung EpiCheck.
Clinical Dx Showcase:
Nucleix
Nucleix is a liquid biopsy company revolutionizing early cancer detection and recurrence monitoring through the Company’s pioneering methylation based EpiCheck® technology. Construction of its Lung Cancer Atlas focuses on stage I disease to provide a high-resolution platform to discover novel, multi-omic biomarkers for cancer screening.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
